Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

US Court Finds Bayer AG’s Yaz Contraceptive Patent Claims Invalid; Actavis Inc, Drug Unit of Novartis AG And Lupin Ltd Involved in Rulling-Reuters


Tuesday, 16 Apr 2013 01:04pm EDT 

Reuters reported that a federal appeals court has ruled against Bayer AG, reversing a ruling by a lower court and finding that parts of a patent for the Company’s Yaz oral contraceptive were invalid. The United States Court of Appeals for the Federal Circuit ruled on April 16, 2013 that a district court in Nevada had erred in finding two claims of a patent for the contraceptive to be not invalid. It reversed the ruling. The generic companies involved in the ruling, Watson Pharmaceuticals, which now goes by the name Actavis Inc, Sandoz Inc - the generic drug unit of Novartis - and Lupin Ltd, had argued that the patent was invalid and had told the United States Food and Drug Administration that they planned to bring out generic versions of the contraceptive. The patent expires on June 30, 2014. 

Company Quote

257.09
2.89 +1.14%
26 Dec 2014